[1]
|
Tanaka, N., Okada, S., Ueno, H., et al. (2000) The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer. Pancreas, 20, 378-382. https://doi.org/10.1097/00006676-200005000-00007
|
[2]
|
朱良如, 侯晓华. 消化系统肿瘤标志物的检测及临床应异[J]. 中国实用内科杂志, 2002, 22(9): 574-576.
|
[3]
|
Akimoto, S., Banshodani, M., Nishihara, M., et al. (2016) Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Reports in Gastroenterology, 10, 410-416. https://doi.org/10.1159/000448068
|
[4]
|
Sheen-Chen, S.M., Sun, C.K., Liu, Y.W., et al. (2007) Extremely Elevated CA19-9 in Acute Cholangitis. Digestive Diseases and Sciences, 52, 3140-3142. https://doi.org/10.1007/s10620-006-9164-7
|
[5]
|
Koprowski, H., Stepleweski, Z., Mitchell, K., et al. (1979) Colorectal Carcinoma Antigens Detected by Hybridoma Antibodies. Somatic Cell and Molecular Genetics, 5, 957-972. https://doi.org/10.1007/BF01542654
|
[6]
|
孔宪涛. 肿瘤特异抗原的研究现状及检测[J]. 中华检验医学杂志, 2000, 23(1): 56-58.
|
[7]
|
尹大龙, 张树庚, 刘连新, 等. CA19-9在良性胆道疾病中表达的临床意义[J]. 中国普通外科杂志, 2009, 18(8): 864-866.
|
[8]
|
Wong, D., Ko, A.H., Hwang, J., et al. (2008) Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Receiving Chemotherapy. Pancreas, 37, 269- 274. https://doi.org/10.1097/MPA.0b013e31816d8185
|
[9]
|
曾立云, 宋逢林, 彭瑛. 胰腺癌血清CA19-9 和CEA的表达及意义[J]. 中国普通外科杂志, 2008, 17(9): 926-928.
|
[10]
|
王怀志, 赵玉亭, 赵国强, 等. 胃癌患者血清CA19-9, CA242联合检测[J]. 中国普通外科杂志, 2004, 13(9): 711- 712.
|
[11]
|
王自正, 李少华, 马伦, 等. 现代医学标记免疫学[M]. 北京: 人民军医出版社, 2000: 57.
|
[12]
|
Ito, S. and Gejyo, F. (1999) Elevation of Serum CA19-9 Levels in Benign Diseases. Internal Medicine, 38, 840-841.
https://doi.org/10.2169/internalmedicine.38.840
|
[13]
|
Yu, H., Yu, T.N. and Cai, X.J. (2013) Tumor Biomarkers: Help or Mislead in the Diagnosis of Xanthogranulomatous Cholecystitis?—Analysis of Serum CA19-9, Carcino-Embryonic Antigen, and CA12-5. Chinese Medical Journal (English), 126, 3044-3047.
|
[14]
|
Ince, A.T., Yıldiz, K., Baysal, B., et al. (2014) Roles of Serum and Biliary CEA, CA19-9, VEGFR3, and TAC in Differentiating between Malignant and Benign Biliary Obstructions. The Turkish Journal of Gastroenterology, 25, 162- 169. https://doi.org/10.5152/tjg.2014.6056
|
[15]
|
Lourdusamy, V., Tharian, B. and Navaneethan, U. (2015) Biomarkers in Bile-Complementing Advanced Endoscopic Imaging in the Diagnosis of Indeterminate Biliary Strictures. World Journal of Gastrointestinal Endoscopy, 7, 308- 317.
|
[16]
|
Mann, D.V., Edwards, R., Ho, S., et al. (2000) Elevated Tumor Marker CAl9-9: Clinical Interpretation and Influence of Obstructive Jaundice. European Journal of Surgical Oncology, 26, 474-479. https://doi.org/10.1053/ejso.1999.0925
|